PL2315773T3 - Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis - Google Patents

Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis

Info

Publication number
PL2315773T3
PL2315773T3 PL09781052T PL09781052T PL2315773T3 PL 2315773 T3 PL2315773 T3 PL 2315773T3 PL 09781052 T PL09781052 T PL 09781052T PL 09781052 T PL09781052 T PL 09781052T PL 2315773 T3 PL2315773 T3 PL 2315773T3
Authority
PL
Poland
Prior art keywords
tubeculosis
polynucleotides
polypeptides
latent
compositions
Prior art date
Application number
PL09781052T
Other languages
Polish (pl)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.
Publication of PL2315773T3 publication Critical patent/PL2315773T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
PL09781052T 2008-07-25 2009-07-24 Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis PL2315773T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
EP09781052.7A EP2315773B1 (en) 2008-07-25 2009-07-24 Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis

Publications (1)

Publication Number Publication Date
PL2315773T3 true PL2315773T3 (en) 2017-07-31

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09781052T PL2315773T3 (en) 2008-07-25 2009-07-24 Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis

Country Status (24)

Country Link
US (2) US20110117119A1 (en)
EP (1) EP2315773B1 (en)
JP (1) JP5873332B2 (en)
KR (1) KR20110044883A (en)
CN (1) CN102164952B (en)
AU (1) AU2009273130B2 (en)
BR (1) BRPI0916703A2 (en)
CA (1) CA2731499C (en)
CO (1) CO6341637A2 (en)
CY (1) CY1118200T1 (en)
DK (1) DK2315773T3 (en)
EA (1) EA024826B1 (en)
ES (1) ES2602430T3 (en)
HR (1) HRP20161458T1 (en)
HU (1) HUE031044T2 (en)
IL (1) IL210559A0 (en)
LT (1) LT2315773T (en)
MX (1) MX2011000983A (en)
PL (1) PL2315773T3 (en)
PT (1) PT2315773T (en)
SG (1) SG192456A1 (en)
SI (1) SI2315773T1 (en)
UA (1) UA107330C2 (en)
WO (1) WO2010010177A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144447B1 (en) * 1998-11-04 2009-10-14 Isis Innovation Limited Tuberculosis diagnostic test
MX2011000982A (en) 2008-07-25 2011-03-02 Glaxosmithkline Biolog Sa The tuberculosis rv2386c protein, compositions and uses thereof.
WO2010010180A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. Novel compositions and methods
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
TR201903223T4 (en) 2009-04-24 2019-03-21 Statens Seruminstitut A tuberculosis TB vaccine to prevent reactivation.
KR20120129927A (en) 2010-01-27 2012-11-28 글락소 그룹 리미티드 Modified tuberculosis antigens
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
EP3049973B1 (en) 2013-09-27 2018-08-08 Codexis, Inc. Automated screening of enzyme variants
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (en) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 A kind of method of vitro detection active tuberculosis
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
BR112021024363A2 (en) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
TR200002938T2 (en) * 1998-04-07 2001-02-21 Corixa Corporation Fusion proteins of microbacterial tuberculosis antigens and their use
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
ES2374620T3 (en) * 2000-06-20 2012-02-20 Corixa Corporation ANTIGEN MTB32A OF MYCOBACTERIUM TUBERCULOSIS WITH THE ACTIVE ACTIVE SITE AND FUSION PROTEINS OF THEMSELVES.
JP3840596B2 (en) * 2001-01-08 2006-11-01 アイシス・イノベーション・リミテッド Assay methods for determining the efficacy of treatments for mycobacterial infections
CN1277843C (en) * 2001-02-22 2006-10-04 巴斯德研究院 Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
KR101352806B1 (en) 2005-04-29 2014-02-17 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Novel method for preventing or treating m tuberculosis infection
EP1910409A2 (en) * 2005-06-23 2008-04-16 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc Compositions and methods for immunodominant antigens
TR201903223T4 (en) * 2009-04-24 2019-03-21 Statens Seruminstitut A tuberculosis TB vaccine to prevent reactivation.
KR20120129927A (en) 2010-01-27 2012-11-28 글락소 그룹 리미티드 Modified tuberculosis antigens

Also Published As

Publication number Publication date
HUE031044T2 (en) 2017-06-28
US9795663B2 (en) 2017-10-24
LT2315773T (en) 2016-11-10
IL210559A0 (en) 2011-03-31
BRPI0916703A2 (en) 2019-12-24
JP5873332B2 (en) 2016-03-01
JP2011528895A (en) 2011-12-01
UA107330C2 (en) 2014-12-25
PT2315773T (en) 2016-11-23
EP2315773B1 (en) 2016-08-24
AU2009273130A1 (en) 2010-01-28
CO6341637A2 (en) 2011-11-21
US20140178423A1 (en) 2014-06-26
EA024826B1 (en) 2016-10-31
CA2731499C (en) 2017-01-10
DK2315773T3 (en) 2016-12-12
EP2315773A1 (en) 2011-05-04
CY1118200T1 (en) 2017-06-28
KR20110044883A (en) 2011-05-02
CN102164952B (en) 2016-05-25
HRP20161458T1 (en) 2016-12-16
CA2731499A1 (en) 2010-01-28
EA201100072A1 (en) 2011-10-31
ES2602430T3 (en) 2017-02-21
US20110117119A1 (en) 2011-05-19
CN102164952A (en) 2011-08-24
MX2011000983A (en) 2011-03-02
WO2010010177A1 (en) 2010-01-28
SG192456A1 (en) 2013-08-30
SI2315773T1 (en) 2016-12-30
AU2009273130B2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
SI2315773T1 (en) Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
PL1975226T3 (en) Liquid treatment composition
EP2314278A4 (en) Hair treatment composition
IL213365A (en) Imidazopyrazine and pharmaceutical compositions comprising the same
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
IL207096A0 (en) Modified leptin polypeptides and their uses
IL195152A (en) Compounds for use in the treatment of cell proliferative disorders
PT2101731T (en) Endoxifen for use in the treatment of cancer
IL215592A (en) Compounds, compositions comprising the same and uses thereof in treating or preventing an ophthalmic condition
PL2190405T3 (en) Hair treatment compositions
EP2172524A4 (en) Resin composition and its use
EP2209458A4 (en) Skin treatment compositions
PL2066408T3 (en) Xanthoxyline-based composition and cosmetic use thereof
GB0719202D0 (en) Compositions and methods for the skin and hair
MX303262B (en) Lotion composition for personal use.
PL2012805T3 (en) Therapeutic composition and use
ZA200905427B (en) Rasp and cover
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0714500D0 (en) composition and treatment
GB2461611B (en) Composition and use thereof
ZA200807154B (en) Liquid treatment composition
GB0622040D0 (en) Skin treatment composition
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii